We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-17.66%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$942M
AUM Growth
-$145M
Cap. Flow
+$138M
Cap. Flow %
14.65%
Top 10 Hldgs %
58.05%
Holding
40
New
8
Increased
12
Reduced
8
Closed
2

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$39.3M
2
RVMD icon
Revolution Medicines
RVMD
+$36.5M
3
TWST icon
Twist Bioscience
TWST
+$18.8M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$13.8M
5
ADVM
Adverum Biotechnologies
ADVM
+$13.1M

Top Sells

Rank Stock Value
1
BOLD
Audentes Therapeutics, Inc
BOLD
+$51.5M
2
ILMN icon
Illumina
ILMN
+$8.62M
3
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$8.09M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$6.39M
5
NVTA
Invitae Corporation
NVTA
+$2.92M

Sector Composition

Rank Sector Weight
1 Healthcare 92.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$90.6M 9.62%
1,550,000
+610,000
+65% +$39.3M
SRPT icon
2
Sarepta Therapeutics
SRPT
$1.63B
$65.5M 6.96%
670,000
– –
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$29.1B
$63.7M 6.76%
585,000
+70,000
+14% +$8.08M
FATE icon
4
Fate Therapeutics
FATE
$294M
$56.6M 6.01%
2,550,000
– –
CDXS icon
5
Codexis
CDXS
$157M
$56.6M 6.01%
5,073,780
– –
BLUE
6
DELISTED
bluebird bio
BLUE
$50.8M 5.39%
85,306
+10,422
+14% +$10.2M
NVTA
7
DELISTED
Invitae Corporation
NVTA
$47.5M 5.05%
3,478,388
-160,000
-4% -$2.92M
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$46.6M 4.95%
995,000
-10,000
-1% -$641K
AGIO icon
9
Agios Pharmaceuticals
AGIO
$1.84B
$38M 4.03%
1,070,000
+245,000
+30% +$11.3M
CNST
10
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$30.8M 3.27%
980,000
-232,734
-19% -$8.09M
TWST icon
11
Twist Bioscience
TWST
$5.97B
$30.6M 3.25%
1,000,000
+700,000
+233% +$18.8M
RVMD icon
12
Revolution Medicines
RVMD
$38.8B
$28.9M 3.07%
+1,319,536
New +$36.5M
CDNA icon
13
CareDx
CDNA
$2.48B
$28.3M 3%
1,294,335
+94,335
+8% +$2.11M
ALEC icon
14
Alector
ALEC
$168M
$26M 2.76%
1,076,039
– –
DNLI icon
15
Denali Therapeutics
DNLI
$3.67B
$25.5M 2.7%
1,455,000
+205,000
+16% +$4.28M
BLFS icon
16
BioLife Solutions
BLFS
$1.56B
$23.5M 2.49%
2,468,571
– –
ADPT icon
17
Adaptive Biotechnologies
ADPT
$3.71B
$22M 2.34%
793,125
+330,000
+71% +$9.2M
DNTH icon
18
Dianthus Therapeutics
DNTH
$5.72B
$18.7M 1.98%
185,690
-7,943
-4% -$1.47M
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
$15.3M 1.63%
300,000
– –
FULC icon
20
Fulcrum Therapeutics
FULC
$280M
$14.4M 1.53%
1,209,285
-30,000
-2% -$480K
GNMK
21
DELISTED
GenMark Diagnostics, Inc
GNMK
$13.9M 1.47%
3,365,000
– –
GRTS
22
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$13.2M 1.4%
2,270,000
+110,000
+5% +$924K
GILD icon
23
Gilead Sciences
GILD
$161B
$13.1M 1.39%
+175,000
New +$12.1M
CRSP icon
24
CRISPR Therapeutics
CRSP
$4.86B
$11.3M 1.2%
+266,430
New +$13.8M
SAGE
25
DELISTED
Sage Therapeutics
SAGE
$11.1M 1.17%
385,000
+155,000
+67% +$8.98M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Casdin Capital held 40 positions worth $942M, down 13% from $1.09B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Casdin Capital deployed $138M of net new capital in Q1 2020, opening 8 new positions and adding to 12 existing holdings. Its largest new stake was Revolution Medicines: 1,319,536 shares worth $28.9M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Illumina, an estimated $8.62M trimmed.

  • Casdin Capital's largest Q1 2020 buy was Revolution Medicines: 1,319,536 shares worth $28.9M.
  • Casdin Capital added most to Blueprint Medicines in Q1 2020, an estimated $39.3M increase.
  • Casdin Capital's biggest Q1 2020 reduction was Illumina, cutting an estimated $8.62M.
  • Casdin Capital fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $51.5M.
  • Casdin Capital's ten largest holdings make up 58% of its $942M portfolio in Q1 2020.
  • Casdin Capital opened 8 new positions and closed 2 in Q1 2020.
  • Casdin Capital's portfolio value fell 13% quarter-over-quarter to $942M.

Based on Casdin Capital's 13F filing for Q1 2020, filed 15 May 2020.